28 results on '"Nozza F"'
Search Results
2. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study
- Author
-
Gerna, G, Baldanti, F, Torsellini, M, Minoli, L, Vigano, M, Oggionni, T, Rampino, T, Castiglioni, B, Goglio, A, Colledan, M, Mammana, C, Nozza, F, Lilleri, D, Gerna G, Baldanti F, Torsellini M, Minoli L, Vigano M, Oggionni T, Rampino T, Castiglioni B, Goglio A, Colledan M, Mammana C, Nozza F, Lilleri D, Gerna, G, Baldanti, F, Torsellini, M, Minoli, L, Vigano, M, Oggionni, T, Rampino, T, Castiglioni, B, Goglio, A, Colledan, M, Mammana, C, Nozza, F, Lilleri, D, Gerna G, Baldanti F, Torsellini M, Minoli L, Vigano M, Oggionni T, Rampino T, Castiglioni B, Goglio A, Colledan M, Mammana C, Nozza F, and Lilleri D
- Abstract
Methods: A bicentre, randomized, prospective open-label study aimed at defining a DNAaemia versus antigenaemia cutoff for guiding preemptive therapy of human cytomegalovirus (HCMV) infections in solid organ transplant recipients (SOTR) was completed. Overall, 99 patients were enrolled in the DNAaemia arm and 101 patients in the antigenaemia arm. Patients were randomized to be monitored for HCMV infection in the blood by either assay. Antiviral treatment was started in both seropositive and seronegative patients when levels greater than 300,000 DNA copies/ml blood or 100 pp65-positive leukocytes in the relevant arm were reached. Results: HCMV infection was detected in 81/99 (81.8%) patients in the DNAaemia arm and in 87/101 (86.1%) patients in the antigenaemia arm (P=ns). Antiviral treatment was given to 23/99 (23.0%) patients in the DNAaemia arm and 42/101 (41.0%) patients in the antigenaemia arm (P=0.01). In the DNAaemia arm, antiviral therapy was significantly delayed and duration of the first course of treatment was significantly greater than in the antigenaemia arm. However, total duration of treatment was comparable in the two arms. No case of HCMV disease occurred in patients treated after reaching the relevant cutoff. However, four patients (three in the antigenaemia arm, and one in the DNAaemia arm) suffered from HCMV disease prior to reaching the relevant cutoff. Conclusions: Compared with antigenaemia, a single DNAaemia cutoff: (i) significantly reduces the number of patients requiring treatment; (ii) may be safely adopted to guide preemptive therapy of both primary and reactivated HCMV infections in SOTR; and (iii) does not significantly modify the overall duration of treatment.
- Published
- 2007
3. Scaning the escherichia coli chromosome by random transposon mutagenesis and multiple screening
- Author
-
Serina, S, Nozza, F, Nicastro, G, Faggioni, F, Mottl, H, Deho, G, POLISSI, ALESSANDRA, Serina, S, Nozza, F, Nicastro, G, Faggioni, F, Mottl, H, Deho, G, and Polissi, A
- Subjects
MUTAGENESI CON TRASPOSONI, MICROBIOLOGIA ,BIO/19 - MICROBIOLOGIA GENERALE - Abstract
Analysis of the complete DNA sequences of many microbial genomes available reveals a fair number of putative ORFs without an identified function. A systematic scan of the Escherichia coli chromosome was achieved by random transposition with a newly developed Tn5 minitransposon derivative carrying the arabinose-inducible araPBAD promoter oriented outward at one end (Tn5-araPBAD). The transposon insertion mutants obtained were assayed for conditional lethal phenotypes (arabinose dependence or sensitivity), for growth at two temperatures (37 and 15°C) and in different media (rich and minimal medium). The Tn5-araPBAD-tagged genes were identified by sequencing the transposon insertion points. In this way we found a new essential gene cluster (yhbN-yhbG), produced conditional lethal (arabinose-dependent) mutations in already known essential genes (folD, frr, plsC, thiL, serS, thrS, and trpS) and provided a new phenotype (cold sensitivity) to other known genes (holD, ahpC, and tolA). Moreover, we identified eight putative ORFs (kch, ycaM, ycbQ, yddA, yddB, ydeK, ydeX, and yliF) that appear to be required in optimum growth conditions (rich medium at 37°C) but not in the cold and in minimal medium. © 2004 Elsevier SAS. All rights reserved.
- Published
- 2004
4. Cell systems and fibre toxicity: in vitro assessment
- Author
-
Giantomassi, F, Pugnaloni, A., Cardile, V., Belluso, Elena, Bloise, Andrea, Fato, R., Graciotti, L., Paoloni, L., Nozza, F., Rinaldi, G., and Biagini, G.
- Published
- 2006
5. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia
- Author
-
Brandimarte, L, Pierini, V, Di Giacomo, D, Borga, C, Nozza, F, Gorello, P, Giordan, M, Cazzaniga, G, Te Kronnie, G, La Starza, R, Mecucci, C, Brandimarte, Lucia, Pierini, Valentina, Di Giacomo, Danika, Borga, Chiara, Nozza, Filomena, Gorello, Paolo, Giordan, Marco, Cazzaniga, Giovanni, Te Kronnie, Geertruy, La Starza, Roberta, Mecucci, Cristina, Brandimarte, L, Pierini, V, Di Giacomo, D, Borga, C, Nozza, F, Gorello, P, Giordan, M, Cazzaniga, G, Te Kronnie, G, La Starza, R, Mecucci, C, Brandimarte, Lucia, Pierini, Valentina, Di Giacomo, Danika, Borga, Chiara, Nozza, Filomena, Gorello, Paolo, Giordan, Marco, Cazzaniga, Giovanni, Te Kronnie, Geertruy, La Starza, Roberta, and Mecucci, Cristina
- Abstract
The MLLT10 gene, located at 10p13, is a known partner of MLL and PICALM in specific leukemic fusions generated from recurrent 11q23 and 11q14 chromosome translocations. Deep sequencing recently identified NAP1L1/12q21 as another MLLT10 partner in T-cell acute lymphoblastic leukemia (T-ALL). In pediatric T-ALL, we have identified 2 RNA processing genes, that is, HNRNPH1/5q35 and DDX3X/Xp11.3 as new MLLT10 fusion partners. Gene expression profile signatures of the HNRNPH1- and DDX3X-MLLT10 fusions placed them in the HOXA subgroup. Remarkably, they were highly similar only to PICALM-MLLT10-positive cases. The present study showed MLLT10 promiscuity in pediatric T-ALL and identified a specific MLLT10 signature within the HOXA subgroup.
- Published
- 2013
6. CONFRONTO TRA I METODI TRADIZIONALI FENOTIPICI ED IL SEQUENZIAMENTO DEL GENE 16S rRNA PER L’IDENTIFICAZIONE DEI BATTERI
- Author
-
Arosio, M., primary, Raglio, A., additional, Nozza, F., additional, Vailati, F., additional, Passera, M., additional, Grigis, A., additional, and Goglio, A., additional
- Published
- 2006
- Full Text
- View/download PDF
7. MONITORAGGIO DELLA PROFILASSI PER LA TUBERCOLOSI LATENTE IN PAZIENTI TRAPIANTATI CON IL TEST T SPOT-TB
- Author
-
Arosio, M., primary, Bargiggia, G., additional, Rizzi, M., additional, Nozza, F., additional, Grigis, A., additional, and Goglio, A., additional
- Published
- 2006
- Full Text
- View/download PDF
8. EBV-DNA E MODULAZIONE DELL’IMMUNO-SOPPRESSIONE NEL CONTROLLO DELLE PTLDs POST TRAPIANTO DI FEGATO PEDIATRICO
- Author
-
Callegaro, A., primary, Nozza, F., additional, Stroppa, P., additional, Torre, G., additional, and Goglio, A., additional
- Published
- 2006
- Full Text
- View/download PDF
9. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia
- Author
-
Marco Giordan, Filomena Nozza, Danika Di Giacomo, Chiara Borga, Geertruy te Kronnie, Cristina Mecucci, Valentina Pierini, Roberta La Starza, Paolo Gorello, Giovanni Cazzaniga, Lucia Brandimarte, Brandimarte, L, Pierini, V, Di Giacomo, D, Borga, C, Nozza, F, Gorello, P, Giordan, M, Cazzaniga, G, Te Kronnie, G, La Starza, R, and Mecucci, C
- Subjects
Oncogene Proteins, Fusion ,Transcription Factor ,Lymphoblastic Leukemia ,Immunology ,Chromosomal translocation ,Biology ,Biochemistry ,Deep sequencing ,Translocation, Genetic ,PICALM ,Transcriptome ,T Acute Lymphoblastic Leukemia ,DEAD-box RNA Helicase ,DEAD-box RNA Helicases ,Humans ,Child ,Gene ,In Situ Hybridization, Fluorescence ,Reverse Transcriptase Polymerase Chain Reaction ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Gene expression profiling ,Cancer research ,Human ,Transcription Factors - Abstract
The MLLT10 gene, located at 10p13, is a known partner of MLL and PICALM in specific leukemic fusions generated from recurrent 11q23 and 11q14 chromosome translocations. Deep sequencing recently identified NAP1L1/12q21 as another MLLT10 partner in T-cell acute lymphoblastic leukemia (T-ALL). In pediatric T-ALL, we have identified 2 RNA processing genes, that is, HNRNPH1/5q35 and DDX3X/Xp11.3 as new MLLT10 fusion partners. Gene expression profile signatures of the HNRNPH1- and DDX3X-MLLT10 fusions placed them in the HOXA subgroup. Remarkably, they were highly similar only to PICALM-MLLT10-positive cases. The present study showed MLLT10 promiscuity in pediatric T-ALL and identified a specific MLLT10 signature within the HOXA subgroup.
- Published
- 2013
10. TERT Gene Promoter Mutations In Myelodysplastic Syndromes (MDS)
- Author
-
Antonella Sgura, Tamara Iannotti, Gianluca Barba, Caterina Matteucci, Valeria Di Battista, Francesco Berardinelli, Filomena Nozza, Cristina Mecucci, Lucia Brandimarte, Valeria Nofrini, Matteucci, C, Iannotti, T, Brandimarte, L, Nofrini, V, Barba, G, Sgura, Antonella, Berardinelli, Francesco, Nozza, F, Di Battista, V, and Mecucci, C.
- Subjects
Sanger sequencing ,Chromosome 7 (human) ,Point mutation ,Immunology ,Nonsense mutation ,Cell Biology ,Hematology ,Biology ,Compound heterozygosity ,Biochemistry ,Molecular biology ,symbols.namesake ,Germline mutation ,Gene duplication ,symbols ,Missense mutation - Abstract
Mutations at the protein-coding region of TERT gene (chromosome 5p15.33) have been well characterized in patients affected by a constitutional telomere syndrome, including diskeratosis, aplastic anemia and pulmonary fibrosis (Calado RT, Hematology, ASH 2009:338). In rare cases somatic mutations may occur in de novo MDS/AML (Calado RT, Young NS. Blood 2008;111:4446). Mutations involving the regulatory region of TERT gene have been recently identified in a consistent proportion of familial and sporadic melanoma and in a subset of tumors originating from tissues with low rate of self-renewal (glioblastoma, liposarcoma, oligodendroglioma bladder cancer, upper urinary tract cancer). These mutations create new binding motifs for Ets/TCF transcription factors, thus increasing TERT gene transcription (Killela PJ et al, PNAS 2013;110:6021; Horn S et al, Science 2013;339:959). As far as we know TERT promoter mutations were never described in MDS. Material and Methods Index Case. A 52 years old woman was selected because of a complex phenotype including abnormal skin pigmentation, familial pulmonary fibrosis, osteoarthritis, and a refractory cytopenia with multilineage dysplasia (RCMD, WHO 2008) with a 47,XX,+8 karyotype. Screening Cases. Mutational analysis was extended to a cohort of 115 patients (72 males; 44 females, median age 69) referred to the Laboratory of Cytogenetics, Hematology Department,University of Perugia, Italy. Cytogenetics was normal in 49 cases (43%). Abnormalities included: isolated del(5q) (seven cases, 6%); del(5q) plus one additional change (three cases, 3%); isolated del(20q) (fourteen cases, 12%); trisomy 8 (five cases, 4%); monosomy 7 (two cases, 2%); -Y (three cases, 3%); del(11q) (two cases, 2%); complex karyotype (twenty-four cases, 21%); other aberrations (six cases, 5%). Genomic DNA was extracted from bone marrow (BM) of all cases and from peripheral blood T lymphocytes of index case using Salting out method. In all cases TERT promoter was screened using PCR based DHPLC assay (Wave system; MD Transgenomic Inc. Omaha, NE). The 274bp amplicon was amplified with forward primer 5'GTCCTGCCCCTTCACCTTC3' and reverse primer 5'AGCACCTCGCGGTAGTGG3' using Robust Start Taq KAPA2G (Biosystems, Woburn, MA). DNA from abnormal elution profiles were re-amplified and sequenced by Sanger method (ABI 3500 Genetic Analyzer, Applied Biosystems). Variations were detected using Finch TV v. 1.4.0. In the index case 23 amplicons encompassing all 16 exons of TERT gene were also screened (NC_000005.9). Mutations cloning was carried out after RNA extraction (Trizol, Invitrogen, Life Technologies, Paisley, UK), reverse transcription (ThermoscriptTM RT-PCR System, Invitrogen) and amplification (TERT_2CF (5'-CAGCGCTACTGGCAAATGCG-3' Ta-61,4°C; and TERT_2543R (5'-GGCACTGGACGTAGGACTTG-3' Ta-61,4°C). PCR products were sub-cloned into pGEM-T easy vector (Promega, Madison, WI, USA) and sequenced. Results Index Case. Patient was a compound heterozygous for two germline variations: a nonsense mutation c.1209C>A p.C403* (exon 2) and a missense mutation c.2455C>T p.R819C (exon 8). A putative somatic A>C transition 57 bp before the ATG start codon was detected only in BM cells (Table). Screening Cases. DHPLC analysis showed three patients (2.6%) with a two-peak elution profile. Sequencing revealed a 10 bp duplication (c.1-110_1-101) in case 2; a c.1-124 C>T point mutation in case 3; a point mutation c.1-78 C>T in case 4 (Table). Comment We showed that TERT gene promoter variations are recurrent events in 2.6% of MDS patients. Only low/int1 risk MDS (IPSS) were affected in this series. The c.1-57A>C, previously reported as a germline activating variation in familial melanoma (Horn S et al, Science 2013;339:959), was likely a somatic mutation in our index case, thus supporting its role in clonal MDS proliferation. We first found the melanoma activating c.1-124 C>T point mutation (Huang FW et al, Science 2013;339:957; Killela PJ et al, PNAS 2013;110:6021) in a MDS with isolated del(5q). The new variation of our case n.4 does not appear to introduce a new transcription factor binding site (http://www.cbrc.jp/research/db/TFSEARCH.html), whereas the 10bp duplication of case 2 indicates an hypothetical binding site for Ikaros. Further results from ongoing functional studies in these cases will be presented. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
11. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: A randomized study
- Author
-
Gerna, Giuseppe, Baldanti, Fausto, Torsellini, Maria, Minoli, Lorenzo, Vigano, Mario, Oggionni, Tiberio, teresa rampino, Castiglioni, Barbara, Goglio, Antonio, Colledan, Michelle, Mammana, Carmelo, Nozza, Francesca, Lilleri, Daniele, Gerna, G, Baldanti, F, Torsellini, M, Minoli, L, Vigano, M, Oggionni, T, Rampino, T, Castiglioni, B, Goglio, A, Colledan, M, Mammana, C, Nozza, F, and Lilleri, D
- Subjects
Adult ,Cytomegalovirus Infection ,Male ,Adolescent ,Cytomegalovirus ,Reproducibility of Result ,Virus Replication ,Antiviral Agents ,Severity of Illness Index ,Drug Administration Schedule ,Viral Matrix Proteins ,Humans ,Pharmacology (medical) ,Prospective Studies ,Viral Matrix Protein ,Aged ,Pharmacology ,Antiviral Agent ,Incidence ,Reproducibility of Results ,Cytomegaloviru ,Organ Transplantation ,Middle Aged ,Viral Load ,Phosphoproteins ,Kidney Transplantation ,Liver Transplantation ,Prospective Studie ,Infectious Diseases ,Italy ,Practice Guideline ,Phosphoprotein ,Cytomegalovirus Infections ,Practice Guidelines as Topic ,DNA, Viral ,Heart Transplantation ,Female ,Human ,Lung Transplantation - Abstract
Methods A bicentre, randomized, prospective open-label study aimed at defining a DNAaemia versus antigenaemia cutoff for guiding preemptive therapy of human cytomegalovirus (HCMV) infections in solid organ transplant recipients (SOTR) was completed. Overall, 99 patients were enrolled in the DNAaemia arm and 101 patients in the antigenaemia arm. Patients were randomized to be monitored for HCMV infection in the blood by either assay. Antiviral treatment was started in both seropositive and seronegative patients when levels greater than 300,000 DNA copies/ml blood or 100 pp65-positive leukocytes in the relevant arm were reached. Results HCMV infection was detected in 81/99 (81.8%) patients in the DNAaemia arm and in 87/101 (86.1%) patients in the antigenaemia arm ( P=ns). Antiviral treatment was given to 23/99 (23.0%) patients in the DNAaemia arm and 42/101 (41.0%) patients in the antigenaemia arm ( P=0.01). In the DNAaemia arm, antiviral therapy was significantly delayed and duration of the first course of treatment was significantly greater than in the antigenaemia arm. However, total duration of treatment was comparable in the two arms. No case of HCMV disease occurred in patients treated after reaching the relevant cutoff. However, four patients (three in the antigenaemia arm, and one in the DNAaemia arm) suffered from HCMV disease prior to reaching the relevant cutoff. Conclusions Compared with antigenaemia, a single DNAaemia cutoff: (i) significantly reduces the number of patients requiring treatment; (ii) may be safely adopted to guide preemptive therapy of both primary and reactivated HCMV infections in SOTR; and (iii) does not significantly modify the overall duration of treatment.
12. Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia.
- Author
-
Valvano L, Nozza F, D'Arena G, D'Auria F, De Luca L, Pietrantuono G, Mansueto G, Villani O, D'Agostino S, Lamorte D, Calice G, and Statuto T
- Subjects
- Humans, T-Lymphocyte Subsets, B-Lymphocytes pathology, Killer Cells, Natural, Flow Cytometry, Leukemia, Lymphocytic, Chronic, B-Cell, Natural Killer T-Cells pathology
- Abstract
Background: B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the expansion of CD5
+ malignant B lymphocytes. Recent discoveries have shown that double-negative T (DNT) cells, double-positive T (DPT) cells, and natural killer T (NKT)-cells may be involved in tumor surveillance., Methods: A detailed immunophenotypic analysis of the peripheral blood T-cell compartment of 50 patients with B-CLL (classified in three prognostic groups) and 38 healthy donors (as controls) matched for age was performed. The samples were analyzed by flow cytometry using a stain-lyse-no wash technique and a comprehensive six-color antibody panels., Results: Our data confirmed a reduction in percentage values and an increase in absolute values of T lymphocytes in patients with B-CLL, as already reported. In particular, DNT, DPT, and NKT-like percentages were significantly lower than in the controls, except for NKT-like in the low-risk prognostic group. Moreover, a significant rise in the absolute counts of DNT cells in each prognostic group and in the low-risk prognostic group of NKT-like cells was found. A significant correlation of the absolute values of NKT-like cells in the intermediate-risk prognostic group versus B cells was observed. Furthermore, we analyzed whether the increase in T cells was related to the subpopulations of interest. Only DNT cells were positively correlated with the increase in CD3+ T lymphocytes, regardless of the stage of the disease, supporting the hypothesis that this T-cell subset plays a key role in the immune T response in B-CLL., Conclusion: These early results supported that DNT, DPT, and NKT-like subsets may be related to disease progression and should encourage further studies aimed at identifying the potential immune surveillance role of these minority T subpopulations., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
13. Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association.
- Author
-
Valvano L, D'Auria F, Grieco V, Statuto T, Nozza F, Pietrantuono G, Villani O, D'Arena G, and Lamorte D
- Abstract
A case of concomitant hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) in a 50- year-old man was reported. Flow cytometry and droplet digital PCR (ddPCR) were used to detect the B-Raf proto-oncogene (BRAF) V600E mutation. The HCL population was the predominant component. The patient was first treated with cladribine and then with rituximab and achieved HCL partial remission. Importantly, the high sensitivity of our flow cytometric approach allowed the detection of a small population "P3," in addition to the typical HCL and CLL clones. The P3 clone changed over time, from an HCL-like to a CLL-like immunophenotype. This case is added to the few other cases of synchronous HCL and CLL already reported in the literature and underlines the importance of analyzing chronic lymphoproliferative disorders by highly sensitive diagnostic techniques, like the multicolor flow cytometry and ddPCR, to evaluate the possible association between HCL and CLL at diagnosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Valvano, D’Auria, Grieco, Statuto, Nozza, Pietrantuono, Villani, D’Arena and Lamorte.)
- Published
- 2022
- Full Text
- View/download PDF
14. Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry.
- Author
-
Statuto T, D'Auria F, Del Vecchio L, Mansueto GR, Villani O, Lalinga AV, Possidente L, Nozza F, Vona G, Rago L, Storto G, Gasparini VR, Zambello R, D'Arena G, and Valvano L
- Abstract
Lymphoproliferative disorders are a heterogeneous group of malignant clonal proliferations of lymphocytes whose diagnosis remains challenging, despite diagnostic criteria are now well established, due to their heterogeneity in clinical presentation and immunophenotypic profile. Lymphoid T-cell disorders are more rarely seen than B-cell entities and more difficult to diagnose for the absence of a specific immunophenotypic signature. Flow cytometry is a useful tool in diagnosing T-cell lymphoproliferative disorders since it is not only able to better characterize T-cell neoplasms but also to resolve some very complicated cases, in particular those in which a small size population of neoplastic cells is available for the analysis. Here, we report three patients with mature T-cell neoplasms with atypical clinical and biological features in which analysis of peripheral blood and bone marrow specimens by means of multicolor flow cytometry was very useful to identify and characterize three rare T-cell lymphoproliferative disorders, such as angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified and T-cell prolymphocytic leukemia. The aim of this case series report is not only to describe three rare cases of lymphoproliferative neoplasms but also to raise awareness that a fast, highly sensitive, and reproducible procedure, such as flow cytometry immunophenotyping, can have a determinant diagnostic role in these patients., Competing Interests: The authors declare that there are no conflicts of interest., (© 2020 Statuto et al.)
- Published
- 2020
- Full Text
- View/download PDF
15. A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain.
- Author
-
Nozza F, Vona G, Trino S, D'Auria F, La Rocca F, Grieco V, Possidente L, De Luca L, and Musto P
- Abstract
Background: Acute promyelocytic leukemia (APL) is characterized by fusion of PML/RARα genes as a result of t(15;17)(q24;q21). APL is now one of the curable hematological malignancies thanks to molecularly targeted therapies based on all-trans retinoic acid (ATRA) and arsenic trioxide (ATX). Extramedullary (EM) relapse is a rare event in APL, ear involvement being even more infrequent, with only six cases so far described. About 30-35% of patients with newly diagnosed APL have additional cytogenetics abnormalities, whose prognostic significance is still controversial. The most common additional aberration is trisomy 8 or partial gain 8q., Case Presentation: We describe here a novel unbalanced translocation der(3)t(3;8)(q29;q23.3-q24.3) associated with 8q partial gain in a 41 year-old man affected by APL in molecular remission after first line treatment, who had a responsive EM relapse in the auditory canal., Conclusions: EM relapse is a rare event in APL and ear involvement is even more infrequent. To our knowledge, this is the first reported case of APL with a new der(3)t(3;8)(q29;q23.3-q24.3) and 8q partial gain associated with t(15;17)(q24;q21). Despite the recurrence of the disease at EM level, the clinical outcome of this patients was favorable., Competing Interests: Competing interestsThe authors declare that they have no competing interests.
- Published
- 2019
- Full Text
- View/download PDF
16. An update on biology, diagnosis and treatment of primary plasma cell leukemia.
- Author
-
Musto P, Statuto T, Valvano L, Grieco V, Nozza F, Vona G, Bochicchio GB, La Rocca F, and D'Auria F
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Prognosis, Stem Cell Transplantation methods, Transplantation, Autologous methods, Leukemia, Plasma Cell diagnosis, Leukemia, Plasma Cell therapy
- Abstract
Introduction: Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendations for the practical management of these patients are provided, with a particular focus on the role of novel agents and transplant procedures. A brief description of the currently ongoing clinical trials with new drugs is also enclosed. Expert opinion: PPCL still represents a difficult challenge for all hematologists. Here the authors provide a personal view on how the current, generally unsatisfactory results in this neoplastic disorder could be improved. In particular, dedicated studies exploring alternative therapies are necessary and eagerly awaited. Such studies should possibly be based on new biological information that could be of help in identifying novel genetic biomarkers for risk stratification and new actionable molecular targets.
- Published
- 2019
- Full Text
- View/download PDF
17. TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination.
- Author
-
Sisinni L, Maddalena F, Condelli V, Pannone G, Simeon V, Li Bergolis V, Lopes E, Piscazzi A, Matassa DS, Mazzoccoli C, Nozza F, Lettini G, Amoroso MR, Bufo P, Esposito F, and Landriscina M
- Subjects
- ATPases Associated with Diverse Cellular Activities, Adult, Aged, Aged, 80 and over, CDC2 Protein Kinase, Cell Line, Tumor, Cyclin B1 metabolism, Cyclin-Dependent Kinases genetics, Female, Gene Expression Regulation, Neoplastic, HSP90 Heat-Shock Proteins genetics, Humans, Ki-67 Antigen metabolism, Mad2 Proteins genetics, Male, Middle Aged, Neoplasms genetics, Neoplasms pathology, Proteasome Endopeptidase Complex metabolism, RNA Interference, Signal Transduction, Time Factors, Transcription, Genetic, Transfection, Ubiquitination, Cell Proliferation, Cyclin-Dependent Kinases metabolism, G2 Phase Cell Cycle Checkpoints, HSP90 Heat-Shock Proteins metabolism, Mad2 Proteins metabolism, Neoplasms enzymology
- Abstract
Regulation of tumour cell proliferation by molecular chaperones is still a complex issue. Here, the role of the HSP90 molecular chaperone TRAP1 in cell cycle regulation was investigated in a wide range of human breast, colorectal, and lung carcinoma cell lines, and tumour specimens. TRAP1 modulates the expression and/or the ubiquitination of key cell cycle regulators through a dual mechanism: (i) transcriptional regulation of CDK1, CYCLIN B1, and MAD2, as suggested by gene expression profiling of TRAP1-silenced breast carcinoma cells; and (ii) post-transcriptional quality control of CDK1 and MAD2, being the ubiquitination of these two proteins enhanced upon TRAP1 down-regulation. Mechanistically, TRAP1 quality control on CDK1 is crucial for its regulation of mitotic entry, since TRAP1 interacts with CDK1 and prevents CDK1 ubiquitination in cooperation with the proteasome regulatory particle TBP7, this representing the limiting factor in TRAP1 regulation of the G2-M transition. Indeed, TRAP1 silencing results in enhanced CDK1 ubiquitination, lack of nuclear translocation of CDK1/cyclin B1 complex, and increased MAD2 degradation, whereas CDK1 forced up-regulation partially rescues low cyclin B1 and MAD2 levels and G2-M transit in a TRAP1-poor background. Consistently, the CDK1 inhibitor RO-3306 is less active in a TRAP1-high background. Finally, a significant correlation was observed between TRAP1 and Ki67, CDK1 and/or MAD2 expression in breast, colorectal, and lung human tumour specimens. This study represents the first evidence that TRAP1 is relevant in the control of the complex machinery that governs cell cycle progression and mitotic entry and provides a strong rationale to regard TRAP1 as a biomarker to select tumours with deregulated cell cycle progression and thus likely poorly responsive to novel cell cycle inhibitors. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd., (Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
18. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
- Author
-
De Luca L, Trino S, Laurenzana I, Tagliaferri D, Falco G, Grieco V, Bianchino G, Nozza F, Campia V, D'Alessio F, La Rocca F, Caivano A, Villani O, Cilloni D, Musto P, and Del Vecchio L
- Subjects
- Annexin A1 genetics, Annexin A1 metabolism, Antagomirs genetics, Antagomirs metabolism, Antigens, CD34 genetics, Antigens, CD34 metabolism, Cell Cycle Checkpoints genetics, Cell Differentiation, Cell Line, Tumor, Early Growth Response Protein 2 genetics, Early Growth Response Protein 2 metabolism, Genetic Vectors chemistry, Genetic Vectors metabolism, Hematopoiesis genetics, Humans, Lentivirus genetics, Lentivirus metabolism, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute pathology, MicroRNAs antagonists & inhibitors, MicroRNAs metabolism, Myeloid Progenitor Cells pathology, Nucleophosmin, Primary Cell Culture, RNA-Binding Proteins metabolism, Signal Transduction, Tristetraprolin genetics, Tristetraprolin metabolism, Gene Expression Regulation, Leukemic, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics, Myeloid Progenitor Cells metabolism, RNA-Binding Proteins genetics
- Abstract
Lin28A is a highly conserved RNA-binding protein that concurs to control the balance between stemness and differentiation in several tissue lineages. Here, we report the role of miR-128a/Lin28A axis in blocking cell differentiation in acute myeloid leukemia (AML), a genetically heterogeneous disease characterized by abnormally controlled proliferation of myeloid progenitor cells accompanied by partial or total inability to undergo terminal differentiation. First, we found Lin28A underexpressed in blast cells from AML patients and AML cell lines as compared with CD34+ normal precursors. In vitro transfection of Lin28A in NPM1-mutated OCI-AML3 cell line significantly triggered cell-cycle arrest and myeloid differentiation, with increased expression of macrophage associate genes (EGR2, ZFP36 and ANXA1). Furthermore, miR-128a, a negative regulator of Lin28A, was found overexpressed in AML cells compared with normal precursors, especially in acute promyelocytic leukemia (APL) and in 'AML with maturation' (according to 2016 WHO classification of myeloid neoplasms and acute leukemia). Its forced overexpression by lentiviral infection in OCI-AML3 downregulated Lin28A with ensuing repression of macrophage-oriented differentiation. Finally, knockdown of miR-128a in OCI-AML3 and in APL/AML leukemic cells (by transfection and lentiviral infection, respectively) induced myeloid cell differentiation and increased expression of Lin28A, EGR2, ZFP36 and ANXA1, reverting myeloid differentiation blockage. In conclusion, our findings revealed a new mechanism for AML differentiation blockage, suggesting new strategies for AML therapy based upon miR-128a inhibition.
- Published
- 2017
- Full Text
- View/download PDF
19. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
- Author
-
Neri A, Todoerti K, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, and Musto P
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Disease Management, Genetic Predisposition to Disease, Genetic Testing methods, Genomics methods, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Plasma Cell etiology, Leukemia, Plasma Cell mortality, Molecular Targeted Therapy, Prognosis, Leukemia, Plasma Cell diagnosis, Leukemia, Plasma Cell therapy
- Abstract
Introduction: Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. The introduction of novel agents and modern technologies has recently partially changed the clinical and biological scenario of this malignancy, allowing limited, but not negligible, progresses. Areas covered: We will discuss: the complex landscape of genetic alterations in PPCL, derived from conventional and high-throughput technologies; the best available treatments for PPCL; the possible future therapeutic perspectives. Expert commentary: PPCL requires an immediate and intensive multi-phase treatment with short therapy-free intervals, which should include novel agents and autologous stem cell transplantation in eligible patients. Allogeneic transplantation should be considered in selected cases. In older and/or frailer individuals, personalized approaches should be applied. Integrated treatments with next generation proteasome inhibitors/IMIDs and monoclonal antibodies are currently planned or under investigation. The identification of novel genomic biomarkers may be potentially helpful for risk stratification and future personalized therapies.
- Published
- 2016
- Full Text
- View/download PDF
20. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
- Author
-
Lionetti M, Barbieri M, Manzoni M, Fabris S, Bandini C, Todoerti K, Nozza F, Rossi D, Musto P, Baldini L, and Neri A
- Subjects
- Cohort Studies, DNA Mutational Analysis methods, Disease Progression, Gene Frequency, Humans, Italy, Multiple Myeloma genetics, Multiple Myeloma pathology, Paraproteinemias pathology, Review Literature as Topic, High-Throughput Nucleotide Sequencing methods, Mutation, Paraproteinemias genetics, Tumor Suppressor Protein p53 genetics
- Abstract
The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications., Competing Interests: The authors declare that they have no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
21. Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.
- Author
-
Musto P, Simeon V, Guariglia R, Bianchino G, Grieco V, Nozza F, La Rocca F, Marziano G, Lalinga AV, Fabiani E, Voso MT, Scaravaglio P, Mecucci C, and D'Arena G
- Abstract
The concomitant presence of del(5q) and JAK2(V617F) mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing - from a clinical, pathological, and biological point of view - for at least some of these patients as a potential distinct entity is discussed.
- Published
- 2014
- Full Text
- View/download PDF
22. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.
- Author
-
Brandimarte L, Pierini V, Di Giacomo D, Borga C, Nozza F, Gorello P, Giordan M, Cazzaniga G, Te Kronnie G, La Starza R, and Mecucci C
- Subjects
- Child, Humans, In Situ Hybridization, Fluorescence, Reverse Transcriptase Polymerase Chain Reaction, Transcriptome, Translocation, Genetic, DEAD-box RNA Helicases genetics, Oncogene Proteins, Fusion genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Transcription Factors genetics
- Abstract
The MLLT10 gene, located at 10p13, is a known partner of MLL and PICALM in specific leukemic fusions generated from recurrent 11q23 and 11q14 chromosome translocations. Deep sequencing recently identified NAP1L1/12q21 as another MLLT10 partner in T-cell acute lymphoblastic leukemia (T-ALL). In pediatric T-ALL, we have identified 2 RNA processing genes, that is, HNRNPH1/5q35 and DDX3X/Xp11.3 as new MLLT10 fusion partners. Gene expression profile signatures of the HNRNPH1- and DDX3X-MLLT10 fusions placed them in the HOXA subgroup. Remarkably, they were highly similar only to PICALM-MLLT10-positive cases. The present study showed MLLT10 promiscuity in pediatric T-ALL and identified a specific MLLT10 signature within the HOXA subgroup.
- Published
- 2013
- Full Text
- View/download PDF
23. Inv(11)(p15q22)/NUP98-DDX10 fusion and isoforms in a new case of de novo acute myeloid leukemia.
- Author
-
Gorello P, Nofrini V, Brandimarte L, Pierini V, Crescenzi B, Nozza F, Daniele G, Storlazzi CT, Di Giacomo D, Matteucci C, La Starza R, and Mecucci C
- Subjects
- Acute Disease, Adult, Amino Acid Sequence, Base Sequence, Chromosome Banding, Exons genetics, Humans, In Situ Hybridization, Fluorescence methods, Karyotype, Male, Molecular Sequence Data, Protein Isoforms genetics, Reverse Transcriptase Polymerase Chain Reaction, Transcription, Genetic, Chromosome Inversion, Chromosomes, Human, Pair 11 genetics, DEAD-box RNA Helicases genetics, Leukemia, Myeloid genetics, Nuclear Pore Complex Proteins genetics, Oncogene Proteins, Fusion genetics
- Abstract
We set up a diagnostic double-color double-fusion fluorescence in situ hybridization (DCDF-FISH) assay to investigate a case of a de novo acute myeloid leukemia (AML)-M4 bearing an inv(11)(p15q22). DCDF-FISH detected the NUP98-DDX10 rearrangement as two fusion signals, at the short and the long arms of the inv(11). Reverse transcription-polymerase chain reaction (RT-PCR) and cloning experiments confirmed the NUP98-DDX10 fusion and identified two splicing fusion isoforms: the known "type II fusion," originating from the fusion of NUP98 exon 14 to DDX10 exon 7 and a new in-frame fusion transcript between NUP98 exon 15 and DDX10 exon 7, which we termed "type III fusion.", (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
24. Evaluation of the MicroSeq 500 16S rDNA-based gene sequencing for the diagnosis of culture-negative bacterial meningitis.
- Author
-
Arosio M, Nozza F, Rizzi M, Ruggeri M, Casella P, Beretta G, Raglio A, and Goglio A
- Subjects
- Adult, Aged, Bacteriological Techniques, Cerebrospinal Fluid microbiology, Child, Child, Preschool, DNA, Bacterial chemistry, DNA, Ribosomal chemistry, Humans, Infant, Meningitis, Bacterial cerebrospinal fluid, Meningitis, Bacterial microbiology, Middle Aged, Polymerase Chain Reaction, Retrospective Studies, Sensitivity and Specificity, Sequence Analysis, DNA, Meningitis, Bacterial diagnosis, Molecular Diagnostic Techniques, RNA, Ribosomal, 16S genetics
- Abstract
Gene amplification using 16S rDNA primers has been proposed as a strategy for the diagnosis of bacterial meningitis. The aim of this study was to evaluate the performance of the MicroSeq 500 16S ribosomal DNA test (Applied Biosystems) from patients with suspected bacterial meningitis and CSF negative-culture in comparison to traditional methods. Twelve purulent culture-negative CSF samples were collected between January 2005 and January 2007. For DNA extraction, 500 microl of CSF samples were treated using the QIAamp mini kit (QIAGEN). The extracted DNA was examined amplifying 500 bp at the 5' end of 16S rRNA gene using MicroSeq500 16S rDNA Bacterial Identification PCR kit and the sequencing reactions were performed with the MicroSeq500 16S rDNA Bacterial Identification Sequencing kit (Applied Biosystems). The sequences were compared with those available in GenBank. For the culture-negative CSF samples the MicroSeq 500 16S rDNA yielded a positive result in 9 cases (75.0%): three samples were identified as Streptococcus. pneumoniae, three as Neisseria meningitidis, and the remaining 3 as Haemophilus influenzae, Abiotrophia defectiva and Porphyromonas gingivalis. The MicroSeq 500 16S ribosomal DNA test may improve the microbiological diagnosis of bacterial meningitis, especially when spinal fluid samples are obtained after the administration of antimicrobial therapy.
- Published
- 2008
25. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
- Author
-
Gerna G, Baldanti F, Torsellini M, Minoli L, Viganò M, Oggionnis T, Rampino T, Castiglioni B, Goglio A, Colledan M, Mammana C, Nozza F, and Daniele L
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents administration & dosage, Cytomegalovirus Infections genetics, Cytomegalovirus Infections immunology, Drug Administration Schedule, Female, Heart Transplantation, Humans, Incidence, Italy epidemiology, Kidney Transplantation, Liver Transplantation, Lung Transplantation, Male, Middle Aged, Practice Guidelines as Topic, Prospective Studies, Reproducibility of Results, Severity of Illness Index, Viral Load, Virus Replication drug effects, Antiviral Agents therapeutic use, Cytomegalovirus genetics, Cytomegalovirus immunology, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections prevention & control, DNA, Viral blood, Organ Transplantation, Phosphoproteins blood, Viral Matrix Proteins blood
- Abstract
Methods: A bicentre, randomized, prospective open-label study aimed at defining a DNAaemia versus antigenaemia cutoff for guiding preemptive therapy of human cytomegalovirus (HCMV) infections in solid organ transplant recipients (SOTR) was completed. Overall, 99 patients were enrolled in the DNAaemia arm and 101 patients in the antigenaemia arm. Patients were randomized to be monitored for HCMV infection in the blood by either assay. Antiviral treatment was started in both seropositive and seronegative patients when levels greater than 300,000 DNA copies/ml blood or 100 pp65-positive leukocytes in the relevant arm were reached., Results: HCMV infection was detected in 81/99 (81.8%) patients in the DNAaemia arm and in 87/101 (86.1%) patients in the antigenaemia arm (P=ns). Antiviral treatment was given to 23/99 (23.0%) patients in the DNAaemia arm and 42/101 (41.0%) patients in the antigenaemia arm (P = 0.01). In the DNAaemia arm, antiviral therapy was significantly delayed and duration of the first course of treatment was significantly greater than in the antigenaemia arm. However, total duration of treatment was comparable in the two arms. No case of HCMV disease occurred in patients treated after reaching the relevant cutoff. However, four patients (three in the antigenaemia arm, and one in the DNAaemia arm) suffered from HCMV disease prior to reaching the relevant cutoff., Conclusions: Compared with antigenaemia, a single DNAaemia cutoff: (i) significantly reduces the number of patients requiring treatment; (ii) may be safely adopted to guide preemptive therapy of both primary and reactivated HCMV infections in SOTR; and (iii) does not significantly modify the overall duration of treatment.
- Published
- 2007
26. Antiviral activity of ovotransferrin derived peptides.
- Author
-
Giansanti F, Massucci MT, Giardi MF, Nozza F, Pulsinelli E, Nicolini C, Botti D, and Antonini G
- Subjects
- Animals, Cells, Cultured, Chick Embryo, Conalbumin chemistry, Lactoferrin chemistry, Lactoferrin pharmacology, Mardivirus drug effects, Peptide Fragments chemistry, Antiviral Agents chemistry, Antiviral Agents pharmacology, Conalbumin pharmacology, Peptide Fragments pharmacology
- Abstract
Ovotransferrin and lactoferrin are iron-binding proteins with antiviral and antibacterial activities related to natural immunity, showing marked sequence and structural homologies. The antiviral activity of two hen ovotransferrin fragments DQKDEYELL (hOtrf(219-227)) and KDLLFK (hOtrf(269-301) and hOtrf(633-638)) towards Marek's disease virus infection of chicken embryo fibroblasts is reported here. These fragments have sequence homology with two bovine lactoferrin fragments with antiviral activity towards herpes simplex virus, suggesting that these fragments could have a role for the exploitation of the antiviral activity of the intact proteins towards herpes viruses. NMR analysis showed that these peptides, chemically synthetized, did not possess any favourite conformation in solution, indicating that both the aminoacid sequence and the conformation they display in the intact protein are essential for the antiviral activity.
- Published
- 2005
- Full Text
- View/download PDF
27. Scanning the Escherichia coli chromosome by random transposon mutagenesis and multiple phenotypic screening.
- Author
-
Serina S, Nozza F, Nicastro G, Faggioni F, Mottl H, Dehò G, and Polissi A
- Subjects
- Chromosomes, Bacterial genetics, Escherichia coli drug effects, Escherichia coli growth & development, Mutation, Phenotype, Plasmids, Promoter Regions, Genetic, Chromosomes, Bacterial chemistry, DNA Transposable Elements genetics, Escherichia coli genetics, Escherichia coli Proteins genetics
- Abstract
Analysis of the complete DNA sequences of many microbial genomes available reveals a fair number of putative ORFs without an identified function. A systematic scan of the Escherichia coli chromosome was achieved by random transposition with a newly developed Tn5 minitransposon derivative carrying the arabinose-inducible araP(BAD) promoter oriented outward at one end (Tn5-araP(BAD)). The transposon insertion mutants obtained were assayed for conditional lethal phenotypes (arabinose dependence or sensitivity), for growth at two temperatures (37 and 15 degrees C) and in different media (rich and minimal medium). The Tn5-araP(BAD)-tagged genes were identified by sequencing the transposon insertion points. In this way we found a new essential gene cluster (yhbN-yhbG), produced conditional lethal (arabinose-dependent) mutations in already known essential genes (folD, frr, plsC, thiL, serS, thrS, and trpS) and provided a new phenotype (cold sensitivity) to other known genes (holD, ahpC, and tolA). Moreover, we identified eight putative ORFs (kch, ycaM, ycbQ, yddA, yddB, ydeK, ydeX, and yliF) that appear to be required in optimum growth conditions (rich medium at 37 degrees C) but not in the cold and in minimal medium.
- Published
- 2004
- Full Text
- View/download PDF
28. Improvement of protein secondary structure prediction by combination of statistical algorithms and circular dichroism.
- Author
-
Carrara EA, Gavotti C, Catasti P, Nozza F, Berutti Bergotto LL, and Nicolini CA
- Subjects
- Databases, Factual, Statistics as Topic, X-Ray Diffraction, Algorithms, Circular Dichroism, Protein Conformation
- Abstract
Three different approaches (propensity curve shifting, hydropathy index evaluation, and iterative attribution/cancellation of secondary structure) to the use of secondary structure percentages derived from circular dichroism measurements to improve the success rate of a protein secondary structure prediction method, without using decision constants, are described and compared. Propensity-curve shifting appears to be the best-performing approach, bearing an increase of 5.3% in the success rate of single-residue structural prediction when exact information on the secondary structure, obtained by X-ray crystallography, is employed; with information of an accuracy comparable to that obtainable by circular dichroism, the improvement stays between 3.5 and 4.9%, for a three-state prediction. Although developed with circular dichroism in mind, the method can use percentages of secondary structure obtained by any other experimental methodology from which they can be inferred, for instance Raman spectroscopy and infrared spectroscopy.
- Published
- 1992
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.